Innoviva’s third quarter 2026 revenue of $106.1M missed estimates despite 45% growth in U.S. product sales

Innoviva reported a top-line miss for the third quarter of 2026, with total revenue declining 1.6% year-over-year. The company recorded a significant net loss driven by a $139.5 million non-cash write-down in the fair value of its equity investments, primarily Armata Pharmaceuticals. Despite the bottom-line impact, the Innoviva Specialty Therapeutics segment demonstrated strong commercial momentum, and management reaffirmed its 2026 guidance for U.S. net product sales.

Key Highlights

• U.S. net product sales surged 45% year-over-year to $43.3 million, led by GIAPREZA at $23.1 million and XACDURO at $16.1 million.
• Royalty revenue from GSK remained stable at $58.1 million, continuing to provide the core cash flow used to fund the infectious disease platform transition.
• The company repurchased 1.2 million shares for $26.3 million during the quarter, with $42.3 million remaining under the current $125 million authorization.